European Archives - Page 166 of 1301 - European Medical Journal

5 Jun 2025

COPD Device Selection Tool

Interactive Devise Selection tool to help select the optimal inhalation therapy device based on patient’s cognitive function, manual dexterity, and peak inspiratory flow for COPD

Infectious Disease Diagnostics: The New Era of STD Screening

In the third episode of our Infectious Disease Diagnostics series, Jonathan sits down with global diagnostics leader Rosanna Peeling to explore the life-saving role of diagnostics in global health, sexually transmitted diseases, and COVID-19.

EASL Congress 2025 Interview: Debbie Shawcross

It always takes a village to organise an event the size of the EASL Congress. We had close to 8,000 registrants, so it was a huge…

Rafael Fonseca

Hema Now: Episode 18: Myeloma Genetics, CAR-T, and Emerging Immunotherapies

Rafael Fonseca, Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA

AI Tool Accurately Predicts Liver Graft Injury Causes

The model analyses demographic information, lab results, and other clinical data to predict the cause of graft injury across six possible conditions.

Immunoglobulin Therapy Slows Kidney Decline in Chronic Rejection, Trial Finds

In a landmark trial, IVIG therapy was shown to slow kidney function decline and tissue damage in patients with chronic active antibody-mediated rejection.

High-Flow Oxygen Shows Limited Benefit in Paediatric Intubation

A major international trial has assessed whether nasal high-flow oxygen improves outcomes during emergency paediatric intubation.

ERA 2025: New Biomarker Model Predicts Kidney Fibrosis in IgA Nephropathy

Selected as a top 10 abstract at the ERA Congress, this study unveils a new multiple biomarker model to predict tubulointerstitial fibrosis in IgA nephropathy without a biopsy.

Respiratory Microbiota Shifts with COVID-19 Severity Progression

New research reveals that the composition of the lower respiratory tract microbiota is closely linked to COVID-19 severity.

How Four Botox Options Differ for Frown Lines

The findings highlight that abobotulinum toxin A and prabotulinum toxin A demonstrated the quickest onset of action.